Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022 • UB-312...
COVID-19
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
- Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial...
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline...
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the...
Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA editing candidate and most advanced...
Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments
BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative...
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid...
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
- Topline Data Expected First Quarter 2023 -DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nabriva...
Lucira Announces Health Canada Authorization of First and Only 99% Accurate At-Home Covid & Flu Test
Lucira COVID-19 & Flu Test – the 99% Accurate At-Home Test for Covid and Flu The first and only at-home...
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data...
Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance
DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in...
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
- FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - -...
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology...
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
Hosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and...
Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform
All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative ColitisSAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Biora...
Albireo Appoints New Members to Board of Directors
– Habib Dable, Former President and CEO of Acceleron Pharma, and Susan Alesina, Vice President, National Business Development and Alliances...
SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines
- Results Demonstrate Significant Anti-Tumor Effects on All Selected Cell Lines - - In Three of the Four Cell Lines,...
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second...
Assure Holdings Sets Second Quarter 2022 Conference Call for Monday, August 15, 2022, at 4:30 p.m. ET
DENVER, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 11th International Conference on Emerging Infectious Diseases (ICEID) on August 7-10, 2022
MIAMI, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...